Anti-tumor mechanism and influencing factors of clinical efficacy of high-dose vitamin C treatment

High-dose vitamin C treatment (HVCT) has demonstrated promising preclinical effects in cancer therapy, yet its clinical translation remains challenging. Despite some benefits in improving quality of life, HVCT has not consistently reproduced superior anti-tumor effects in cancer patients. This article delves into the anti-tumor mechanisms of HVCT, focusing on oxidative stress, and explores potential reasons for its limited clinical success. Cancer factors, such as advanced staging and the uncertainty of sensitive cancer types, as well as research factors, including dosing inconsistencies and methodological variations, contribute to this challenge. To address these issues, standardization of dosing, exploration of novel formulations, and identification of reliable therapeutic targets are crucial. HVCT’s low toxicity, cost-effectiveness, and anticancer selectivity highlight its potential in tumor metabolism therapy. However, further standardized, precise, and intensified clinical studies are urgently needed to fully unlock its therapeutic potential. In summary, while HVCT shows promise, its clinical application requires further optimization and exploration. By addressing the current challenges, we hope to realize the full benefits of HVCT in cancer treatment.